Cancer immunotherapy using DNA vaccination

Drugs of the Future

Volumn 22, Issue 7, 1997, Pages 747-756

  Pandha, Hardev S ^a   Martin, Lesley Ann ^a   Sikora, Karol ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; NONHUMAN; ONCOGENE; REVIEW; VACCINATION;

EID: 0030873085     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259: 1745-9.
2. Donnelley, J. et al. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nat Med 1995, 1: 583-7.
3. Wolff, J.A. et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247: 1465-8.
4. Allison, J. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994, 6: 414-9.
5. Korkolopoulou, P., Kaklamanis, L., Pezzella, F., Harris, A.L., Gatter, K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996, 73: 148-53.
6. Pardoll, D. New strategies for active immunotherapy with genetically engineered tumour cells. Curr Opin Immunol 1992, 4: 619-23.
7. Hersey, P., Smith, M., Thomas, W. Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 1994, 58: 527-32.
8. Klein, R.M., Wolf, E.D., Wu, R., Sanford, J.C. High-velocity microprojectiles for delivering nucleic acids into living cells. Biotechnology 1992, 24: 384-6.
9. Cheng, L., Ziegelhoffer, P.R., Yang, N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993, 90: 4455-9.
10. Condon, C., Watkins, S.C., Celluzzi, C.M., Thompson, K., Falo, L.D. Jr. DNA-basedimmunization by in vivo transfection of dendritic cells. Nat Med 1996, 2: 1122-8.
11. 32P injected intraperitoneally into rats. Nature 1959, 184: 1818-9.
12. Davis, H.L., Demeneix, B.A., Quantin, B., Coulombe, J., Whalen, R.G. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993, 4: 733-40.
13. Buttrick, P.M., Kass, A., Kitsis, R.N., Kaplan, M.L., Leinwand, L.A. Behavior of genes directly injected into the rat heart in vivo. Circ Res 1992, 70: 193-8.
14. Wu, G.W. et al. Fate of DNA targeted to hepatocytes by asialoglycoprotein polylysine conjugates. Proc Assoc Am Phys 1995, 107: 211-7.
15. Ebbinghaus, S.W. et al. Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. Gene Ther 1996, 3: 287-97.
16. Feigner, J.H. et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994, 269: 2550-61.
17. + cytotoxic T cells. J Exp Med 1990, 172: 1083-90.
18. Flynn, J.L. et al. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol 1990, 4: 2111-8.
19. Pan, Z.K., Ikonomidis, G., Lazenby, A., Pardoll, D.Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour challenge and causes regression of established tumours. Nat Med 1995, 1: 471-7.
20. Germain, R. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 1994, 76: 287-99.
21. Falk, K., Rotsche, O., Stevenovic, S., Jung, G., Ramanassee, H.G Allele-specific motifs revealed by sequencing of self pepetides eluted from MHC molecules. Nature 1991, 351: 290-6.
22. Sijts, E., Ossendorp, F., Mengede, E., Van den Elsen, P., Melief, C. An immunodominant MCF murine leukaemia virus encoded CTL epitope identified by its MHC class I binding motif, explains MuLV specificty of MCF-directed CTL. J Immunol 1994, 152: 106-16.
23. Syrengelas, A.D., Chen, T.T., Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996, 2: 1038-41.
24. Stevenson, F. et al. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995, 145: 211-28.
25. Losman, M., Hansen, H., Sharkey, R., Goldenberg, D., Monestier, M. Human responses against NP-4, a mouse antibody to carcinoembryonic antigen: Human anti-idiotypic antibodies mimic an epitope on the tumour antigen. Proc Natl Acad Sci USA 1991, 88: 3421-5.
26. Lane, D.P. p53 and human cancers. Br Med Bull 1994, 50: 582-99.
27. + cytotoxic T-cells. Cancer Res 1993, 53: 3257-61.
28. Ciernik, I.F., Berzofsky, J.A., Carbone, D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996, 156: 2369-75.
29. Bos, J.L. The ras gene family and human carcinogenesis. Mutat Res 1988, 195: 255-71.
30. Fenton, R.G., Taub, D.D., Kwak, L.W., Smith, M.R., Longo, D.L. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 1993, 85: 1294-302.
31. + T cells from a patient with colon carcinoma, specific for a mutant p21-ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995, 40: 165-72.
32. Gedde Dahl, T.D., Eriksen, J.A., Thorsby, E., Gaudernack, G. T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derivad synthetic peptides. Hum Immunol 1992, 33: 266-74.
33. Gedde Dahl, T.D., Fossum, B., Eriksen, J.A., Thorsby, E., Gaudernack, G. T cell clones specific for p21 ras-derivad peptides: Characterization of their fine specificity and HLA restriction. Eur J Immunol 1993, 23: 754-60.
34. Possum, B. et al. Overlapping epitopes encompassing a point mutation (12 Gly→Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol 1993, 23: 2687-91.
35. Skipper, J., Stauss, H.J. Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J Exp Med 1993, 177: 1493-8.
36. Gjertsen, M.K. et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 1995, 346: 1399-400.
37. Traversal, V., van der Bruggen, P., Luescher, I.F., Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognised on HLA-A1 by cytotoxic T-lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992, 176: 1453-7.
38. Kawakami, Y., Robbins, P.F., Rosenberg, S.A. Human melanoma antigens recognised by T-lymphocytes. Keio J Med 1996, 45: 100-8.
39. Kantor, J. et al. Antitumour activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992, 84: 1084-91.
40. Conry, R.M. et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995, 2: 59-65.
41. Gendler, S.J. et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990, 265: 15286-93.
42. Burchell, J. et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987, 47: 5476-82.
43. Kotera, Y., Fontenot, J.D., Pecher, G., Metzgar, R.S., Finn, O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994, 54: 2856-60.
44. Ioannides, C.G. et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993, 151: 3693-703.
45. Domenech, N. In vivo studies of MHC-restricted recognition of a peptide from the MUC-1 tandem repeat domain by cytotoxic T lymphocytes. FASEB J 1995, A1023.
46. Hareuveni, M. et al. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990, 87: 9498-502.
47. Acres, R.B., Hareuveni, M., Balloul, J.M., Kieny, M.P. Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of marine tumors bearing the MUC1 antigen. J Immunother 1993, 14: 136-43.
48. Graham, R., Burchell, J. Intramuscular immunisation with MUC-1 cDNA can protect C57 mice challenged with MUC-1-expressing syngeneic tumour cells. Int J Cancer 1996, 65: 664-70.
49. Muñoz, N., Bosch, F., De San Jose, S. The causal link between HPV and invasive cervical cancer: A population study based in Columbia and Spain. Int J Cancer 1992, 52: 743-9.
50. Vousden, K. Mechanisms of transformation by human papilloma virus. In: Human Papillomavirus and Cervical Cancer - Biology and Immunology. Stern, P., Stanley, M. (Eds.). Oxford Medical Publications: Oxford 1994, 92-115.
51. Campo, M. et al. Prophylactic and therapeutic vaccination against a mucosal papilloma virus. J Gen Virol 1993, 74: 945-53.
52. Meneguzzi, G., Cerni, C., Kieny, M., Lathe, R. Immunisation against human papilloma virus type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991, 181: 62-9.
53. Borysiewicz, L.K. et al. A recombinant vaccinia virus encoding human papilloma virus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347: 1523-7.
54. Pardoll, D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995, 13: 399-415.
55. Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71: 1093-102.
56. Chen, L., Linsley, P., Hellstrom, K. Costimulation of T cells for mature immunity. Immunol Today 1993, 14: 483-6.
57. Steinman, R. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991, 9: 271-96.
58. Corr, M., Lee, D., Carson, D., Tighe, H. Gene vaccination with nakedplasmid DNA: Mechanism of CTL priming. J Exp Med 1996, 184: 1555-60.
59. Mayordomo, J., Zorina, T. Bone marrow-derived dendritic cells pulsed with synthetic peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1: 1297-302.
60. Hsu, F., Benike, C., Fagnoni, F., Lues, T., Levy, R. Vaccination of patients with B cell lymphoma using autologous anyigen-pulsed dendritic cells. Nat Med 1996, 2: 52-8.
61. Henderson, R. et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumour antigen mucin (MUC-1). Cancer Res 1996, 56: 3763-70.
62. Reeves, M., Royal, R., Lam, J., Rosenberg, S., Hwu, P. Retroviral transduction of human dendritic cells with a tumour-associated antigen gene. Cancer Res 1996, 56: 5672-7.
63. Rouse, R., Nair, S., Lydy, S., Bowen, J.R. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex viral proteins. J Virol 1994, 68: 5685-9.